ScoreWhy is Shanghai Rendu Biotechnology Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 17.05%
- The company has been able to generate a Return on Capital Employed (avg) of 17.05% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -18.72% and Operating profit at -213.53% over the last 5 years
- DIVIDEND PAYOUT RATIO(Y) Highest at 116.91%
- RAW MATERIAL COST(Y) Fallen by -5.3% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -84.84 %
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 33.21%, its profits have fallen by -143.7%
4
Market Beating Performance
- The stock has generated a return of 33.21% in the last 1 year, much higher than market (China Shanghai Composite) returns of 22.49%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Shanghai Rendu Biotechnology Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Shanghai Rendu Biotechnology Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shanghai Rendu Biotechnology Co., Ltd.
-100.0%
1.93
41.85%
China Shanghai Composite
16.01%
1.58
14.20%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-18.72%
EBIT Growth (5y)
-213.53%
EBIT to Interest (avg)
-6.82
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.19
Tax Ratio
42.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.05%
ROE (avg)
2.04%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.06
EV to EBIT
-26.86
EV to EBITDA
-53.51
EV to Capital Employed
9.74
EV to Sales
6.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-36.27%
ROE (Latest)
-1.02%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
DIVIDEND PAYOUT RATIO(Y)
Highest at 116.91%
RAW MATERIAL COST(Y)
Fallen by -5.3% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -84.84 %
DIVIDEND PER SHARE(HY)
Highest at CNY 2.85
OPERATING PROFIT(Q)
Highest at CNY 1.9 MM
OPERATING PROFIT MARGIN(Q)
Highest at 5 %
PRE-TAX PROFIT(Q)
Highest at CNY 4.31 MM
NET PROFIT(Q)
Highest at CNY 3.26 MM
EPS(Q)
Highest at CNY 0.13
-8What is not working for the Company
INTEREST(HY)
At CNY 0.13 MM has Grown at 59.79%
NET SALES(Q)
Lowest at CNY 37.91 MM
Here's what is working for Shanghai Rendu Biotechnology Co., Ltd.
Net Profit
At CNY 3.26 MM has Grown at 240.99%
over average net sales of the previous four periods of CNY -2.31 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Pre-Tax Profit
At CNY 4.31 MM has Grown at 193.45%
over average net sales of the previous four periods of CNY -4.62 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Operating Profit
Highest at CNY 1.9 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 5 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at CNY 4.31 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Net Profit
Highest at CNY 3.26 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
EPS
Highest at CNY 0.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CNY)
Debt-Equity Ratio
Lowest at -84.84 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Dividend per share
Highest at CNY 2.85
in the last five yearsMOJO Watch
Company is distributing higher dividend from profits generated
DPS (CNY)
Dividend Payout Ratio
Highest at 116.91%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
Raw Material Cost
Fallen by -5.3% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Shanghai Rendu Biotechnology Co., Ltd.
Interest
At CNY 0.13 MM has Grown at 59.79%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Net Sales
Lowest at CNY 37.91 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Net Sales
At CNY 37.91 MM has Fallen at -11.79%
over average net sales of the previous four periods of CNY 42.98 MMMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
